Immune phenotype and immune checkpoint inhibitors for the treatment of human hepatocellular carcinoma
N Nishida, M Kudo - Cancers, 2020 - mdpi.com
Immunotherapies are promising approaches for treating hepatocellular carcinomas (HCCs)
refractory to conventional therapies. However, a recent clinical trial of immune checkpoint …
refractory to conventional therapies. However, a recent clinical trial of immune checkpoint …
Classification and prognosis prediction from histopathological images of hepatocellular carcinoma by a fully automated pipeline based on machine learning
Objective The aim of this study was to develop quantitative feature-based models from
histopathological images to distinguish hepatocellular carcinoma (HCC) from adjacent …
histopathological images to distinguish hepatocellular carcinoma (HCC) from adjacent …
[HTML][HTML] PD-1 does not mark tumor-infiltrating CD8+ T cell dysfunction in human gastric cancer
Background Overexpression of programmed cell death protein 1 (PD-1) is linked to CD8+ T
cell dysfunction and contributes to tumor immune escape. However, the prevalence and …
cell dysfunction and contributes to tumor immune escape. However, the prevalence and …
PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
Purpose: Immune-checkpoint inhibitors have shown therapeutic efficacy in various
malignant diseases. However, anti-programmed death (PD)-1 therapy has not shown …
malignant diseases. However, anti-programmed death (PD)-1 therapy has not shown …
Implication of CD69+CD103+ tissue‐resident‐like CD8+ T cells as a potential immunotherapeutic target for cholangiocarcinoma
Background The heterogeneous immune landscapes of intrahepatic cholangiocarcinoma
(ICC) remain largely unknown. Here we aimed to investigate the implications of tissue …
(ICC) remain largely unknown. Here we aimed to investigate the implications of tissue …
Evolving tumor characteristics and smart nanodrugs for tumor immunotherapy
W Sun, S Xie, SF Liu, X Hu, D Xing - International Journal of …, 2024 - Taylor & Francis
Typical physiological characteristics of tumors, such as weak acidity, low oxygen content,
and upregulation of certain enzymes in the tumor microenvironment (TME), provide survival …
and upregulation of certain enzymes in the tumor microenvironment (TME), provide survival …
Immunotherapy for hepatocellular carcinoma: new prospects for the cancer therapy
R Fasano, MA Shadbad, O Brunetti, A Argentiero… - Life, 2021 - mdpi.com
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death
worldwide. HCC patients may benefit from liver transplantation, hepatic resection …
worldwide. HCC patients may benefit from liver transplantation, hepatic resection …
PD-1/PD-L1–Associated Immunoarchitectural Patterns Stratify Pancreatic Cancer Patients into Prognostic/Predictive Subgroups
E Karamitopoulou, A Andreou… - Cancer immunology …, 2021 - AACR
Abstract Immunotherapy, including PD-1/PD-L1 agonists, has shown limited efficacy in
pancreatic ductal adenocarcinoma (PDAC). We examined the PD-1/PD-L1 expression and …
pancreatic ductal adenocarcinoma (PDAC). We examined the PD-1/PD-L1 expression and …
Rationale of immunotherapy in hepatocellular carcinoma and its potential biomarkers
Hepatocellular carcinoma (HCC), the most common type of liver cancer, is derived mostly
from a background of chronic inflammation. Multiple immunotherapeutic strategies have …
from a background of chronic inflammation. Multiple immunotherapeutic strategies have …
[HTML][HTML] Association between genetic and immunological background of hepatocellular carcinoma and expression of programmed cell death-1
N Nishida, K Sakai, M Morita, T Aoki, M Takita… - Liver Cancer, 2020 - karger.com
Abstract Background and Aim: Immune checkpoint inhibitors are promising agents for the
treatment of hepatocellular carcinomas (HCC) refractory to conventional therapies. To …
treatment of hepatocellular carcinomas (HCC) refractory to conventional therapies. To …